Medtronic to Unveil Additional Clinical Data on HVAD® System at ISHLT 2018
Data on Implant Approach, Blood Pressure Management, Length of Stay, and Quality of Life
to be Featured During Congress.
DUBLIN - April 9, 2018 - Medtronic plc (MDT) today announced a preview of notable clinical data on the HeartWare HVAD® System that will be presented at The International Society of Heart and Lung Transplantation (ISHLT) Scientific Sessions, from April 11-14, 2018, in Nice, France. The HVAD System is a mechanical heart pump (also called a left ventricular assist device, or LVAD) that helps increase the amount of blood that flows through the body in patients with advanced heart failure.
"ISHLT is the pre-eminent gathering of clinicians involved in caring for patients with advanced heart or lung disease, including heart transplants and mechanical circulatory support. Medtronic is pleased to collaborate with physicians to share the latest clinical evidence that advances MCS therapy," said Mike Hess, general manager of the Mechanical Circulatory Support business, part of the Cardiac and Vascular Group at Medtronic.
The congress agenda highlights several presentations featuring the HVAD System (all times CEST):
Wednesday, April 11
8:30-10 a.m., Apollon: Blood Pressure Management Ameliorates the Severity of Neurological Events, JJ Teuteberg, Stanford University
Thursday, April 12
6:15-7:15 p.m., Uranie/Calliope: An Analysis of Preceding Signals and Treatment Strategies of VAD Thrombus in the ENDURANCE and ENDURANCE SUPPLEMENTAL Trials, FD Pagani, University of Michigan
Friday, April 13
6:15-7:15 p.m., Hermes: Infections and Subsequent Events in the ENDURANCE and ENDURANCE Supplemental Trials, RL Kormos, University of Pittsburgh
Saturday, April 14
1:15 p.m., Athena: The Effects of Concomitant Procedures at the Time of LVAD Implant for Patients in the ENDURANCE and ENDURANCE Supplemental Trials, NA Mokadam, University of Washington
Featured posters include:
Adverse Events and their Effect on Quality of Life and Functional Capacity in the ENDURANCE and ENDURANCE Supplemental Trials
Does Increasing Experience in Implementing the Blood Pressure Management Protocol in the ENDURANCE Supplemental Trial Result in Better Outcomes?
Change in Heart Rate from Pre-Implant to Discharge in Destination Therapy is Associated with Mortality and Admissions in LVAD Patients - A Substudy of the ENDURANCE trial
Details such as times, presenters and locations are subject to change.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world`s largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 84,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic`s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
-end-
Contacts:
Tracy McNulty
Public Relations
+1-763-526-2492
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medtronic plc via GlobeNewswire
HUG#2182913
